Characterization of Different Forms of Kava (Piper methysticum) Products by UPLC-MS/MS

Abstract

There are several forms of kava (Piper methysticum) products available for human consumption, and many factors are known to influence their chemical compositions and therefore their pharmacological properties. Because of the increased popularity of kava intake, a rigorous characterization of their content diversity is prerequisite, particularly due to its known potential to cause hepatotoxicity. To understand the composition diversity of kavalactones and flavokavains in commercial kava products, we developed a UPLC-MS/MS-based analytical method for the quantification of six kavalactones (kavain, dihydrokavain, methysticin, dihydromethysticin, yangonin and desmethoxyyangonin) and two flavokavains (flavokavains A and B) and analyzed their contents in 28 different kava products in the form of capsules, tinctures, traditional aqueous suspensions and dried powders. Our results demonstrated a great variation in terms of the total and relative abundance of the analyzed kavalactones and flavokavains among the analyzed kava preparations. More importantly, the kavalactone abundance in the product label could differ up to 90% from our experimental measurements. Therefore, more rigorous and comprehensive quality control of kava products is required with respect to the content of individual kavalactones and flavokavains. Accurate content information is essential to understand the pharmacological properties and safety of different kava products.

Key words

Kava - kavalactones - flavokavains - UPLC-MS/MS - Piper methysticum - Piperaceae

Publication History

Received: 27 July 2021

Accepted after revision: 28 November 2021

Accepted Manuscript online:
28 November 2021

Article published online:
22 August 2022

• References

• 1 Volgin A, Yang L, Amstislavskaya T, Demin K, Wang D, Yan D, Wang J, Wang M, Alpyshov E, Hu G, Serikuly N, Shevyrin V, Wappler-Guzzetta E, de Abreu M, Kalueff A. DARK classics in chemical neuroscience: Kava. ACS Chemical Neuroscience 2020;
• 2 WHO. Kava: A review of the safety of tradtional and recreational beverage consumption. Food and Agriculture Organization of the United Nation 2016; 1: 1-35
• 3 Wheatley D. Kava and valerian in the treatment of stress-induced insomnia. Phytother Res 2001; 15: 549-551
• 4 Ooi SL, Henderson P, Pak SC. Kava for generalized anxiety disorder: a review of current evidence. Journal of alternative and complementary medicine 2018;
• 5 Münte TF, Heinze HJ, Matzke M, Steitz J. Effects of oxazepam and an extract of kava roots (Piper methysticum) on event-related potentials in a word recognition task. Neuropsychobiology 1993; 27: 46-53
• 6 Pollastri MP, Whitty A, Merrill JC, Tang X, Ashton TD, Amar S. Identification and characterization of kava-derived compounds mediating TNF-alpha suppression. Chem Biol Drug Des 2009; 74: 121-128
• 7 Johnson TE, Kassie F, OʼSullivan MG, Negia M, Hanson TE, Upadhyaya P, Ruvolo PP, Hecht SS, Xing C. Chemopreventive effect of kava on 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumorigenesis in A/J mice. Cancer Prev Res (Phila) 2008; 1: 430-438
• 8 Leitzman P, Narayanapillai SC, Balbo S, Zhou B, Upadhyaya P, Shaik AA, OʼSullivan MG, Hecht SS, Lu J, Xing C. Kava blocks 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in association with reducing O6-methylguanine DNA adduct in A/J mice. Cancer Prev Res 2014; 7: 86-96
• 9 Johnson TE, Hermanson D, Wang L, Kassie F, Upadhyaya P, OʼSullivan MG, Hecht SS, Lu J, Xing C. Lung tumorigenesis suppressing effects of a commercial kava extract and its selected compounds in A/J mice. Am J Chin Med 2011; 39: 727-742
• 10 Narayanapillai SC, Balbo S, Leitzman P, Grill AE, Upadhyaya P, Shaik AA, Zhou B, OʼSullivan MG, Peterson LA, Lu J, Hecht SS, Xing C. Dihydromethysticin from kava blocks tobacco carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis and differentially reduces DNA damage in A/J mice. Carcinogenesis 2014; 35: 2365-2372
• 11 Tang SN, Zhang J, Jiang P, Datta P, Leitzman P, OʼSullivan MG, Jiang C, Xing C, Lü J. Gene expression signatures associated with suppression of TRAMP prostate carcinogenesis by a kavalactone-rich kava fraction. Mol Carcinog 2016; 55: 2291-2303
• 12 Triolet J, Shaik AA, Gallaher DD, OʼSullivan MG, Xing C. Reduction in colon cancer risk by consumption of kava or kava fractions in carcinogen-treated rats. Nutr Cancer 2012; 64: 838-846
• 13 Einbond LS, Negrin A, Kulakowski DM, Wu HA, Antonetti V, Jalees F, Law W, Roller M, Redenti S, Kennelly EJ, Balick MJ. Traditional preparations of kava (Piper methysticum) inhibit the growth of human colon cancer cells in vitro . Phytomedicine 2017; 24: 1-13
• 14 Li X, Liu Z, Xu X, Blair CA, Sun Z, Xie J, Lilly MB, Zi X. Kava components down-regulate expression of AR and AR splice variants and reduce growth in patient-derived prostate cancer xenografts in mice. PLoS One 2012; 7: e31213-e31213
• 15 Bian T, Corral P, Wang Y, Botello J, Kingston R, Daniels T, Salloum RG, Johnston E, Huo Z, Lu J, Liu AC, Xing C. Kava as a clinical nutrient: promises and challenges. Nutrients 2020; 12: 3044
• 16 Teschke R, Schwarzenboeck A, Hennermann KH. Kava hepatotoxicity: a clinical survey and critical analysis of 26 suspected cases. Eur J Gastroenterol Hepatol 2008; 20: 1182-1193
• 17 Côté CS, Kor C, Cohen J, Auclair K. Composition and biological activity of traditional and commercial kava extracts. Biochem Biophys Res Commun 2004; 322: 147-152
• 18 Teschke R, Qiu SX, Lebot V. Herbal hepatotoxicity by kava: Update on pipermethystine, flavokavain B, and mould hepatotoxins as primarily assumed culprits. Dig Liver Dis 2011; 43: 676-681
• 19 Coulter D, Tamayo C, Sotheeswaran S, Ulbricht C. World Health Organization. Assessment of the risk of hepatotoxicity with kava products. Geneva: World Health Organization; 2007. Accessed January 14, 2022 at: https://apps.who.int/iris/handle/10665/43630
• 20 Olsen LR, Grillo MP, Skonberg C. Constituents in kava extracts potentially involved in hepatotoxicity: a review. Chem Res Toxicol 2011; 24: 992-1002
• 21 Clouatre DL. Kava kava: Examining new reports of toxicity. Toxicol Lett 2004; 150: 85-96
• 22 Stickel F, Baumüller HM, Seitz K, Vasilakis D, Seitz G, Seitz HK, Schuppan D. Hepatitis induced by Kava (Piper methysticum rhizoma). J Hepatol 2003; 39: 62-67
• 23 Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS One 2014; 9: e111572
• 24 Mohanty M. Fiji Kava: production, trade, role and challenges. JPacS 2017; 37: 5-30
• 25 Nelson S. Farm and forestry production and marketing profile for kava (Piper methysticum). In: Elevitch CR. ed. Specialty Crops for Pacific Island. Holualoa, HI: Agroforestry Publisher, Permanent Agriculture Resources; 2021
• 26 Johnston E, Rogers H. eds. Hawaiian ‘Awa: views of an ethnobotanical treasure. Hilo, HI: Association for Hawaiian ‘Awa; 2006
• 27 Bian T, Corral P, Wang Y, Botello J, Kingston R, Daniels T, Salloum RG, Johnston E, Huo Z, Lu J, Liu AC, Xing C. Kava as a clinical nutrient: Promises and challenges. Nutrients 2020; 12: 3044
• 28 Lebot V, Michalet S, Legendre L. Kavalactones and flavokavins profiles contribute to quality assessment of kava (Piper methysticum G. Forst.), the traditional beverage of the pacific. Beverages 2019; 5: 34
• 29 Lebot V, Do TK, Legendre L. Detection of flavokavins (A, B, C) in cultivars of kava (Piper methysticum) using high performance thin layer chromatography (HPTLC). Food Chem 2014; 151: 554-560
• 30 Martin AC, Johnston E, Xing C, Hegeman AD. Measuring the chemical and cytotoxic variability of commercially available kava (Piper methysticum G. Forster). PLoS One 2014; 9: e111572
• 31 Li Y, Mei H, Wu Q, Zhang S, Fang JL, Shi L, Guo L. Methysticin and 7,8-dihydromethysticin are two major kavalactones in kava extract to induce CYP1A1. Toxicol Sci 2011; 124: 388-399
• 32 Zhou P, Gross S, Liu JH, Yu BY, Feng LL, Nolta J, Sharma V, Piwnica-Worms D, Qiu SX. Flavokawain B, the hepatotoxic constituent from kava root, induces GSH-sensitive oxidative stress through modulation of IKK/NF-kappa B and MAPK signaling pathways. FASEB J 2010; 24: 4722-4732
• 33 Narayanapillai SC, Leitzman P, OʼSullivan MG, Xing C. Flavokawains a and b in kava, not dihydromethysticin, potentiate acetaminophen-induced hepatotoxicity in C57BL/6 mice. Chem Res Toxicol 2014; 27: 1871-1876
• 34 [Anonymous] ICH harmonised tripartite guideline. Q2(R1): Validation of Analytical Procedures: Text and Methodology. Accessed April 20, 2021 at: https://database.ich.org/sites/default/files/Q2_R1__Guideline.pdf
• 35 Lasme P, Davrieux F, Montet D, Lebot V. Quantification of kavalactones and determination of kava (Piper methysticum) chemotypes using near-infrared reflectance spectroscopy for quality control in vanuatu. J Agric Food Chem 2008; 56: 4976-4981
• 36 Pluskal T, Torrens-Spence MP, Fallon TR, De Abreu A, Shi CH, Weng JK. The biosynthetic origin of psychoactive kavalactones in kava. Nat Plants 2019; 5: 867-878
• 37 Shaik AA, Hermanson DL, Xing C. Identification of methysticin as a potent and non-toxic NF-kappaB inhibitor from kava, potentially responsible for kavaʼs chemopreventive activity. Bioorg Med Chem Lett 2009; 19: 5732-5736
• 38 Srinivasan B, Johnson TE, Xing C. Chalcone-based inhibitors against hypoxia-inducible factor 1–structure activity relationship studies. Bioorg Med Chem Lett 2011; 21: 555-557